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Two double-blind studies comparing the effectiveness 
of the cyclic nucleotide-altering agent (4-[3-butoxy-4-
methoxybenzyl]-2-imidazoHdinone) (Ro 20-1724) vs ve· 
hicle have demonstrated that this compound can im· 
prove psoriatic lesions. Although Ro 20-1724 was not as 
effective as intensive occlusive treatment of psoriatic 
lesions with 0.025 % triamcinolone acetonide, Ro 20-1724 
had no adverse systemic or cutaneous effects. Ro 20-1724 
and other cyclic nucleotide-altering agents may have 
therapeutic potential in the future treatment of pso-
riasis. 
Psoriasis is the prototype of several common steroid sensitive 
proliferative skin diseases and afflicts approximately 1 to 2% of 
the population [1). Although the precise role of cyclic nucleo-
tides in psoriasis remains unclear [2-6], most investigators do 
agree that the epidermal cyclic nucleotide metabolism in pso-
riatic plaques may be misregulated. 
Recent investigations [7] with the cyclic nucleotide phospho-
diestera e (PDE) inhibitors papaverine and Ro 20-1724 (4-[3-
butoxy-4-methoxybenzyl]-2-irnidazolidinone) have shown that 
papaverine inhibits both cAMP-PDE and cGMP-PDE, whereas 
Ro 20-1724 selectively inhibits only cAMP-PDE. Furthermore, 
when psoriatic epidermis was incubated with papaverine or Ro 
20-1724, Ro 20-1724 increa ed the levels of cAMP significantly 
greater than papaverine incubations. These studies clearly dem-
onstrated the superiority of Ro 20-1724 to selectively elevate 
cAMP levels in in ubated psoriatic epidermis. 
Since the topical application of I% papaverine cream pro-
duces a modest but significant improvement of psoriatic lesions 
[8], we anticipated that the marked in vitro superiority of Ro 
20-1724 to e levate cyclic AMP levels and its lipophilic character 
would also result in the improvement of psoriatic lesions. There-
fore, we investigated the clinical effectiveness of Ro 20-1724 in 
3 double-blind clinical studies with psoriatic patients. In these 
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studies, we compared the clinical effectiveness of Ro 20-1724 to 
vehicle and to 0.025% triamcinolone acetonide. 
MATERIALS AND METHODS 
Comparison of I % Ro 20-1724 Cream and its Vehicle 
Seventeen outpatients with typical plaques of psoriasis, who had not 
treated the disease for one week, participated in a double-blind clinical 
tudy. Two lesions approximately 5 em in diameter were selected on 
each patient and designated as site l and site 2. 
Patients were 18 yr of age or older, with no history of significant 
cardiovascular disease. Women chosen were postmenopausal, had had 
a hysterectomy or were on oral-contraceptives. Patients being treated 
with insulin or oral hypoglycemics were not accepted to the study. For 
this clinical evaluation the creams were supplied by Hoffman-LaRoche, 
Inc., Nutley, New Jersey. The vehicle cream contained: glyceryl mon-
ostereate, cetyl alcohol, white petrolatum, methylparaben, prophypar-
aben, propylene glycol, and purified water. The Ro 20-1724 formulation 
consisted of the same cream with Ro 20-1724 added to a 1% final 
concentration. Each patient received vehicle cream and Ro 20 cream in 
tube containers. One of each pair of tubes had been randomly desig-
nated for use on site 1 and the other for use on site 2. Both creams had 
the same color. The code was not broken until completion of the study. 
Patients applied the creams 4 times a day for 4 weeks under occlu-
sion. The total occlusion was approximately 20 hr per day. Topical 
steroids and systemic medication for psoriasis were not permitted to be 
used concurrently. Clinical laboratory studies were conducted on all 
patients before using the creams and at the fiiSt 2 ubsequent visits. 
The laboratory parameters obtained included electrolytes, urea nitro-
gen, total bilirubin, gluco e, total protein, albumin, cholesterol, calcium, 
phosphorus. uric acid, creatinine, glutamic oxaloacetic transaminase, 
lactic dehydrogenase, alkaline phosphatase, white blood count, hema-
tocrit, hemoglobin, red blood count and urine analysis for sugar, ketones 
and proteins. 
Each test lesion was evaluated independently by 2 phy icians, 2, 4 
and 6 weeks after the initiation of the study. The final evaluation at 6 
weeks was made following a 2-week period with no application. Im-
provement was judged by a decrease in lesion thickness, not by a lo 
of scale or change in color. Each lesion was assigned a score of 0 on the 
first day and improvement from the initial status was scored as follows: 
0 = no improvement or worsening, I = minimal improvement, 2 = 
moderate improvement (decreased thickness and/or incomplete clear-
ing). 3 =complete clearing with or without residual redness or change 
in pigmentation. When 2 phy icians disagreed in their evaluation, the 
lower score was used for statistical analysis. cores of 2 and 3 were 
called improved, and core of 0 and 1 w~re called unimproved in the 
analysis of the results at either 2, 4 or six weeks of application. 
Patients showing differential improvement, i.e., who had a lesion 
respond to Ro 20 while the matched lesion did not respond to a vehicle, 
or who had a lesion respond to vehicle while the matched lesion did 
not respond to Ro 20, were used for statistical evaluations employing 
a sign test [9]. 
Comparison of 3 Ro 20-1724 Concentrations at the Unh•ersity of 
Miami 
A second study comparing Ro 20 at concentrations of 0.25%, 0.5%, 
and I '{. vs vehicle cream was conducted at the University of Miami by 
one of us (G.W.) in part to look for a dose response effect. Nine patients 
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were treated simultaneously with three Ro 20 concentrations and 
vehicle cream in a double-blind psoriasis therapeutic study. Patients 
did not receive any systemic or topical anti psoriatic medications during 
the study. On multiple similar psoriatic plaques, 10 sites were delineated 
approximately 1-\1/' square which were randomly assigned to be treated 
with the different Ro 20 concentrations and vehicle cream. Approxi-
mately 0.5 ml of each concentration of Ro 20 and vehicle were applied 
in duplicate to the appropriate sites. The remaining 2 sites were 
untreated controls. Creams were applied daily under occlusion for 6 
days, treatment was stopped on the 7th day, then applications were 
resumed for an additional6 days. All test applications in the study were 
made by a technician to insure the greatest accuracy in the drug being 
applied each time to the same site. Each site was scored as 0 if there 
was no change from initial status, 1 + if there was minimal improvement, 
and 2+ if there was substantial improvement or clearing. Daily evalu-
ations were recorded after the treated sites had been washed with water 
and acetone. The final evaluation was made on the 15th day, 2 days 
after the final treatment. 
Comparison of I % Ro 20·I724 Cream and 0.025% Triamcinolone 
Acetonide Cream 
Thirty-three outpatients participated in a third study which com-
pared the effect of 1% Ro 20-1724 vs 0.025% triamcinolone (TMC). The 
patients and psoriatic lesions were selected in the identical manner to 
the frrst study. The TMC was in a vehicle which contained: sorbic acid, 
potassium sorbate, mono- and diglycerides, squalane, polysorbate 80 
USP, stearyl alcohol USP, polysorbate 60, spermaceti USP, and sorbitol 
solution USP in a water base. This vehicle and that for Ro 20 were 
identical in color and odor. The Ro 20 formulation was identical to that 
used in the frrst clinical study. The methods of application and evalu-
ation from the first study were employed (see "Comparison of 1% Ro 
20-1724 Cream and its Vehicle"). 
RESULTS AND DISCUSSION 
Twelve of 17 patients completed the first clinical study. Two 
patients were disqualified because they did not occlude the 
lesions regularly, and 3 requested to be removed because their 
untreated psoriasis was flaring. The clinical laboratory studies 
did not reveal any abnormalities which could be attributed to 
1% Ro 20-1724. 
Table I summarizes the data obtained from the 4th week 
evaluation of those 12 patients. Nine of 12, 75%, of the patients 
improved only with the Ro 20 preparation and 8% (1 of 12) 
improved only with the vehicle. The Ro 20 treated site was 
improved in 9 of 10 patients showing differential improvement 
(p = .011). 
The results of this study can be compared with the results of 
the previously reported papaverine vs vehicle psoriasis bioassay 
[8). Utilizing the percent relative difference ± SE [10), the 
proportion of patients expected to improve with 1% Ro 20 or 
1% PAP cream who did not improve with the respective vehicle 
creams can be determined. This comparison shows that Ro 20 
is a much superior agent in treating psoriasis since 73 ± 15% of 
patients would be expected to improve with 1% Ro 20 cream in 
contrast to only 39 ± 12% receiving 1% PAP cream (p = .05). 
Nine psoriasis patients completed the second (University of 
Miami) clinical study. All 54 sites treated with the 3 concentra-
tions of Ro 20-1724 showed either minimal or substantial im-
provement (Table II) . The placebo preparation had only 4 
minimial responses out of 18 test sites suggesting a definite 
TABLE I. Percent of 12 psoriasis patients with matched lesions 
responding to I % Ro 20-1724 us vehicle at 4 weeks." 
Improved on both Ro 20-1724 and vehicle 
Improved on Ro 20-1724 only 
Improved on vehicle only 
Unimproved on both 
Sign test (one-sided hypothesis) 
Percent 
0 
75• 
s• 
_!1 
100 
• p = .011 
"Categorized into 4 possible patterns of response (improved on both, 
improved on Ro 20 only, improved on vehicle only, unimproved on 
both) 
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therapeutic effect from the Ro 20-1724 preparations (p < .01). 
A dose related effect is suggested at the 0.25% concentration 
however, this concentration may also be too high to demon~ 
strate this point. 
Thirty of thirty-three patients completed the third clinical 
study. Two patients were dropped from the study because they 
did not apply the creams regularly and the other patient was 
disqualified because he did not occlude the lesions. None of the 
clinical laboratory studies revealed any abnormalities attribut-
able to 1% Ro 20-1724. 
The results of the second and the fourth week evaluation of 
those 30 patients are summarized in Table III. Every patient 
whose Ro 20-treated lesion improved by the 4th week also 
improved on TMC. The difference in the time course of im-
provement for TMC and Ro 20 can be seen in Table IV. Eighty-
six percent of the patients had improved on TMC at the second 
week and the increase to 94% at the fourth week was not 
significant (p = .25). By contrast, the percentage for Ro in-
creased from 43 to 77 which is significant (p < .001). Ro 20 and 
TMC appeared to be clinically similar. 
Eight of the njne patients judged completely cleared at the 
4th week on Ro 20 were seen 2 weeks after the applications 
were discontinued. Six of 8 (75%) had begun to relapse. Twenty 
of 23 patients who cleared completely on TMC were evaluated 
after two weeks without application. Eight of these (40%) 
partially relapsed. 
These investigations indicate that Ro 20-1724 is capable of 
improving psoriasis. In 2 double-blind studies comparing Ro 20-
1724 vs vehicle, Ro 20-1724 significantly improved psoriasis in 
geographically distinct (Michigan and Florida) patient popula-
tions. Although Ro 20-1724 is not as effective as 0.025% triam-
cinolone acetonide applied q.i .d. under occlusion, no atrophy, 
striae or other adverse steroid effects would be expected with 
Ro 20-1724 application. 
The currently available therapeutic modalities to treat pso-
riasis have inherent limitations that restrict their effectiveness. 
Of those most commonly employed, topical steroids can induce 
atrophy and striae and UVB irradiation with topical coal tar 
usually requires hospitalization. Furthermore, the risk factors 
TABLE II. Clinical effect.~ by drug concentration of Ro 20-1724 on 
psoriasis" 
Number of tesl sites at each 
Concentrations of Ro concenLration 
20- 1724 
1% .5% .25% Placebo 
Response 
2 ll ll 8 0 
I 7 7 10 4 
0 0 0 0 14 
"Each of the nine patients tested in duplicate sites with the prepa-
rations above (see text) . A possible dose response effect may be present 
at the 0.25% concentration. Response was graded as follows: no im-
provement = 0, minimal improvement = I , and moderate or better 
improvement = 2. 
TABLE Ill. Percent of 30 psoriasis patients with matched lesions 
responding to 1% Ro 20· I 724 us 0.025% triamcinolone categorized 
into the 4 possible patterns of response at 2 & 4 weeks" 
Percent 
2nd Week 4th Week 
Improved on both Ro 20-1724 43 77 
and Triamcinolone 
Improved on Ro 20-1724 only o· Ot 
Improved on Triamcinolone 43. 17t 
only 
Unimproved on both 
_l1 6 
100 100 
Sign test (one-sided hypothesis) • p < .001 t p = .03 
" Improved on both, improved on Ro 20 only, improved on TMC 
only, unimproved on both. 
Oct. 1979 
TABLE IV. Percent of lesions improved in 30 psoriasis patients on 
.025% triamcinolone and 1% Ro 20·1724 at2 & 4 weeks 
Triamcinolone-treated 
Ro 20-1724-treated 
2nd Week 
Percent 
4th Week•• 
94° 
77t 
Sign test (one-sided hypothesis) • p = .25, t p < .001. 
" All lesions improved at 2nd week were also improved at 4th week. 
of PUV A cannot be objectively assessed at this time. Ro 20-
1724 and other cyclic nucleotide-altering agents are experimen-
tal agents that may have future potential in the treatment of 
p~o~iasis. Such agents may provide topical therapy with a 
mmunum of adverse side effects which can be used as alterna-
tive forms of treatment for patients with psoriasis who are 
unable to use conventional forms of therapy. 
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ANNOUNCEMENT 
The Center for Disease Control of the Public Health Service is again offering a continuing series of short, 
intensive laboratory training courses during 1979-1980. Information and applications may be obtained from the 
registrar, Bureau of Laboratories, Center for Disease Control, Atlanta, Georgia 30333. 
